Nallapareddy, Sujatha
2 papers on CoChat
Most cited papers
- Verified
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology
Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases
Cited by 552
- Verified
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 259
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free